Dr. Abbey Reports on New Method to Measure Retinal Fluid After Treatment with Faricimab for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored an article in the medical journal Eye on the use of a novel deep-learning algorithm to quantify retinal fluid changes in patients treated with
read more
Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more
Dr. Abbey Presented 2.5 Year Results of the TRUCKEE Study at The Retina Society Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study – 2.5 Year Results” at the 57thAnnual Scientific Meeting of
read more Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more
What is an Amsler Grid?
An Amsler grid is a tool that can help detect early signs of retinal disease that affect the macula which is the center of vision in the retina. Age-related macular degeneration (AMD)
read more Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more
Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more
February is AMD/Low Vision Awareness Month
By Ivan G. Castillo, MD February is national age-related macular degeneration (AMD) and low vision awareness month. Low vision is a visual impairment that cannot be corrected by standard eyeglasses, contact lenses, medication
read more